Key facts
- This page summarizes Peter Wijngaard's Form 4 filing for Hepion Pharmaceuticals, Inc. (HEPA).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 28 Nov 2023, 06:55.
Peter Wijngaard - 24 Nov 2023 Form 4 Insider Report for Hepion Pharmaceuticals, Inc. (HEPA)
- Reporting relationship
- Director
- Issuer ticker
- HEPA
- Reported as of
- 24 Nov 2023
- Net transaction value
- +$15,350
- SEC form
- 4
- Accepted by SEC
- 28 Nov 2023, 06:55:05 UTC
- Prior SEC filing
- 20 Sep 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Peter Wijngaard
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Peter Wijngaard filed Form 4 for Hepion Pharmaceuticals, Inc. (HEPA) on 28 Nov 2023.
Change
- Previous filing in this sequence was filed on 20 Sep 2023.
- Current net transaction value: +$15,350.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
HEPA
transaction
Common Stock
Purchase
- Transaction value
- $7,725
- Shares
- +2,500
- Change %
- +56%
- Price
- $3.09
- Shares after
- 7,001
- Date
- 24 Nov 2023
- Ownership
- Direct
HEPA
transaction
Common Stock
Purchase
- Transaction value
- $7,625
- Shares
- +2,500
- Change %
- +36%
- Price
- $3.05
- Shares after
- 9,501
- Date
- 27 Nov 2023
- Ownership
- Direct
* marks a reported price that did not pass the local price check.